FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2162805000> ?p ?o ?g. }

• W2162805000 endingPage "92" @default.
• W2162805000 startingPage "84" @default.
• W2162805000 abstract "Among new highly potent antagonistic analogs of luteinizing hormone-releasing hormone (LH-RH), containing neutral hydrophilic D-ureidoalkyl amino acids such as D-Cit and D-Hci at position 6 and free of edematogenic and anaphylactoid reactions, Ac-D-Nal(2)1, D-Ph(4Cl)2, D-Pa1(3)3, D-Cit6, D-Ala10 (LH-RH) (SB-75; Cetrorelix) was shown to be one of the most powerful. In this trial, we evaluated the response to 500 μg SB-75 given every 12 hr subcutaneously (sc) for 4 weeks in 11 patients with benign prostatic hyperplasia (BPH), and 6 weeks in 6 prostatic cancer patients (2 stage C, 4 stage D2). In patients with BPH presenting with prostatism and urinary outflow obstruction, there was a noticeable clinical improvement after the first week of SB-75 administration. This improvement continued during the course of treatment. Before therapy with SB-75, the serum levels of prostate-specific antigen (PSA) (6.73 ± 1.46 ng/ml), acid phosphatases, total (12.67 ± 1.15 U/l), and prostatic (2.27 ± 0.34 U/l), were mildly elevated, but declined to normal values at 4 weeks: (2.13 ± 0.59 ng/ml; P < 0.01), (7.68 ± 0.89 U/l; P < 0.01), and (1.39 ± 0.18 U/l; P < 0.01), respectively. Mean prostatic volume assessed by ultrasonography showed a significant decrease in all patients from 67.84 ± 8.86 to 37.92 ± 8.52 cm3; P < 0.01, which represents a reduction of 44%. In patients with prostate cancer, after the first week of therapy with SB-75, we observed a significant decrease in bone pain, relief in urinary outflow obstruction, and reversal of the signs of prostatism. Subjective improvement continued during the following weeks of treatment, so that the patients no longer needed analgesics. PSA, acid, and alkaline phosphatases gradually fell, achieving nearly normal values at 6 weeks. Initial serum testosterone levels in BPH and prostatic cancer patients were within normal limits, but during treatment with the antagonistic analog SB-75, fell to castration values. A major fall in free testosterone levels was observed after the first dose; the maximal inhibition was seen after 6-12 hr, with a simultaneous decrease in levels of both gonadotropins. Our results show that antagonist 58-75 can be safely administered for prolonged periods of time. The rapid shrinkage of the prostate and concomitant improvement in obstructive symptoms of prostatism obtained with antagonistic analog SB-75 in patients with BPH may decrease the morbidity of prostatic surgery and offer a therapeutic alternative in men who are considered poor surgical risks. Antagonist SB-75 could also be useful for the treatment of prostatic cancer, but further studies are required. © 1994 Wiley-Liss, Inc." @default.
• W2162805000 created "2016-06-24" @default.
• W2162805000 creator A5000046527 @default.
• W2162805000 creator A5038582703 @default.
• W2162805000 creator A5040619933 @default.
• W2162805000 creator A5056596376 @default.
• W2162805000 creator A5063296502 @default.
• W2162805000 creator A5065367273 @default.
• W2162805000 creator A5068739269 @default.
• W2162805000 creator A5089639285 @default.
• W2162805000 date "1994-02-01" @default.
• W2162805000 modified "2023-10-18" @default.
• W2162805000 title "Responses to the antagonistic analog of LH-RH (SB-75, cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer" @default.
• W2162805000 cites W1964344836 @default.
• W2162805000 cites W1964499150 @default.
• W2162805000 cites W1971459148 @default.
• W2162805000 cites W1972020194 @default.
• W2162805000 cites W1972879180 @default.
• W2162805000 cites W1980245302 @default.
• W2162805000 cites W1986451811 @default.
• W2162805000 cites W2011205608 @default.
• W2162805000 cites W2019811067 @default.
• W2162805000 cites W2022690114 @default.
• W2162805000 cites W2037678459 @default.
• W2162805000 cites W2038243639 @default.
• W2162805000 cites W2049215610 @default.
• W2162805000 cites W2050015894 @default.
• W2162805000 cites W2050430224 @default.
• W2162805000 cites W2051202032 @default.
• W2162805000 cites W2051270818 @default.
• W2162805000 cites W2056888601 @default.
• W2162805000 cites W2073640546 @default.
• W2162805000 cites W2088295630 @default.
• W2162805000 cites W2093410615 @default.
• W2162805000 cites W2112336468 @default.
• W2162805000 cites W2318158772 @default.
• W2162805000 doi "https://doi.org/10.1002/pros.2990240206" @default.
• W2162805000 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7508623" @default.
• W2162805000 hasPublicationYear "1994" @default.
• W2162805000 type Work @default.
• W2162805000 sameAs 2162805000 @default.
• W2162805000 citedByCount "87" @default.
• W2162805000 countsByYear W21628050002012 @default.
• W2162805000 countsByYear W21628050002013 @default.
• W2162805000 countsByYear W21628050002014 @default.
• W2162805000 countsByYear W21628050002015 @default.
• W2162805000 countsByYear W21628050002017 @default.
• W2162805000 countsByYear W21628050002018 @default.
• W2162805000 countsByYear W21628050002021 @default.
• W2162805000 crossrefType "journal-article" @default.
• W2162805000 hasAuthorship W2162805000A5000046527 @default.
• W2162805000 hasAuthorship W2162805000A5038582703 @default.
• W2162805000 hasAuthorship W2162805000A5040619933 @default.
• W2162805000 hasAuthorship W2162805000A5056596376 @default.
• W2162805000 hasAuthorship W2162805000A5063296502 @default.
• W2162805000 hasAuthorship W2162805000A5065367273 @default.
• W2162805000 hasAuthorship W2162805000A5068739269 @default.
• W2162805000 hasAuthorship W2162805000A5089639285 @default.
• W2162805000 hasConcept C121608353 @default.
• W2162805000 hasConcept C126322002 @default.
• W2162805000 hasConcept C126894567 @default.
• W2162805000 hasConcept C134018914 @default.
• W2162805000 hasConcept C2776235491 @default.
• W2162805000 hasConcept C2776490512 @default.
• W2162805000 hasConcept C2777562237 @default.
• W2162805000 hasConcept C2780192828 @default.
• W2162805000 hasConcept C2781406297 @default.
• W2162805000 hasConcept C2910675164 @default.
• W2162805000 hasConcept C2994223898 @default.
• W2162805000 hasConcept C71924100 @default.
• W2162805000 hasConceptScore W2162805000C121608353 @default.
• W2162805000 hasConceptScore W2162805000C126322002 @default.
• W2162805000 hasConceptScore W2162805000C126894567 @default.
• W2162805000 hasConceptScore W2162805000C134018914 @default.
• W2162805000 hasConceptScore W2162805000C2776235491 @default.
• W2162805000 hasConceptScore W2162805000C2776490512 @default.
• W2162805000 hasConceptScore W2162805000C2777562237 @default.
• W2162805000 hasConceptScore W2162805000C2780192828 @default.
• W2162805000 hasConceptScore W2162805000C2781406297 @default.
• W2162805000 hasConceptScore W2162805000C2910675164 @default.
• W2162805000 hasConceptScore W2162805000C2994223898 @default.
• W2162805000 hasConceptScore W2162805000C71924100 @default.
• W2162805000 hasIssue "2" @default.
• W2162805000 hasLocation W21628050001 @default.
• W2162805000 hasLocation W21628050002 @default.
• W2162805000 hasOpenAccess W2162805000 @default.
• W2162805000 hasPrimaryLocation W21628050001 @default.
• W2162805000 hasRelatedWork W1980188241 @default.
• W2162805000 hasRelatedWork W2038565121 @default.
• W2162805000 hasRelatedWork W2390043372 @default.
• W2162805000 hasRelatedWork W2410966200 @default.
• W2162805000 hasRelatedWork W2413659195 @default.
• W2162805000 hasRelatedWork W2418772805 @default.
• W2162805000 hasRelatedWork W2525053981 @default.
• W2162805000 hasRelatedWork W2897445903 @default.
• W2162805000 hasRelatedWork W3047346330 @default.
• W2162805000 hasRelatedWork W4290194839 @default.
• W2162805000 hasVolume "24" @default.

• next